Zheng Quan Shi Bao Wang·2025-08-14 14:22Group 1 - Company successfully issued China's first private pharmaceutical industry medium to long-term technology innovation bond with a scale of 1 billion RMB and a maturity of 2 years at a coupon rate of 2.70% [2] - The bond attracted enthusiastic subscriptions from various financial institutions, including bank wealth management, insurance, foreign banks, public funds, and securities firms [2] - Funds raised from this bond will support the company's layout in key technology innovation areas, accelerating the transformation and implementation of innovative results, and enhancing its global competitiveness in the pharmaceutical and health industry [2] Group 2 - Company has focused on innovation as its core development driver for over 30 years, with 12 self-developed and licensed innovative drugs approved since 2019 [3] - Four products with five indications have been approved in China and the EU since 2025, including the first self-developed small molecule innovative drug, which fills a gap in the rare tumor field [3] - The anti-PD-1 monoclonal antibody has become the first PD-1 monoclonal antibody approved in the EU for the treatment of extensive-stage small cell lung cancer, marking significant progress in international expansion [3]